Doxycycline |
Catalog No.GC63621
One-Click Copy Product Info
|
Doxycycline es un antibiótico de amplio espectro derivado de tetracycline, que inhibe la síntesis de proteínas al interferir con la unión de aminoacyl-tRNAs activados en el sitio A de la subunidad 30S de los ribosomas bacterianos.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 564-25-0
Sample solution is provided at 25 µL, 10mM.
Doxycycline es un antibiótico de amplio espectro derivado de tetracycline, que inhibe la síntesis de proteínas al interferir con la unión de aminoacyl-tRNAs activados en el sitio A de la subunidad 30S de los ribosomas bacterianos. Se utiliza para tratr una variedad de infecciones causadas por bacterias y protozoos. Doxycycline también es un inhibidor inespecífico de metalloproteinase (MMP). Doxycycline exhibe actividad anti-tumour y pro-apoptotic [1-4].
Doxycycline(0-250 µM; 72h) inhibe la viabilidad celular de las células y las mammospheres[5]. Doxycycline (100 ng/mL, 1 µg/mL; 24 h) reduce la proliferación de líneas celulares humanas[6].
Doxycycline(20mg /kg; p.o.;2 vecess) tratada después de que los ratones TBI mejoró la función conductual y motora, lo que sugiere el papel de doxycycline en la preservación de la integridad de BBB murina[7]. Doxycycline(DOX en agua potable (6 mg/ml, 5 ml/día/ratones) ; 36 días) minimizó significativamente el fenotipo distrófico de los núsculos esqueléticos y cardíacos y mejoró la fuerza muscular de las hermillas abiertas[8]. The FM( microbiota fecal) de las hembras C57BL/6NCrl se altera significativamente por la administración de doxycycline(doxycycline en el agua potable a 2 mg/ml durante las semanas 1, 2, y 4) a una concentración de 2 mg/ml en el agua potable[9].
References:
[1]. Cunha BA, Sibley CM, et,al. Doxycycline. Ther Drug Monit. 1982;4(2):115-35. doi: 10.1097/00007691-198206000-00001. PMID: 7048645.
[2].Manchado E, Weissmueller S, et,al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51. doi: 10.1038/nature18600. Epub 2016 Jun 22. PMID: 27338794; PMCID: PMC4939262.
[3].Luger AL, Sauer B, et,al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504. doi: 10.3390/ijms19051504. PMID: 29772845; PMCID: PMC5983704.
[4]. Duivenvoorden WC, Popović SV, et,al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002 Mar 15;62(6):1588-91. PMID: 11912125.
[5]. Zhang L, Xu L, et,al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. doi: 10.1080/15384101.2016.1241929. Epub 2016 Oct 18. PMID: 27753527; PMCID: PMC5405729.
[6]. Ahler E, Sullivan WJ, et,al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561. doi: 10.1371/journal.pone.0064561. PMID: 23741339; PMCID: PMC3669316.
[7]. Malek AJ, Robinson BD, et,al. Doxycycline improves traumatic brain injury outcomes in a murine survival model. J Trauma Acute Care Surg. 2020 Sep;89(3):435-440. doi: 10.1097/TA.0000000000002801. PMID: 32467458.
[8]. Pereira JA, Taniguti AP, et,al. Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice. Muscle Nerve. 2012 Sep;46(3):400-6. doi: 10.1002/mus.23331. PMID: 22907231.
[9]. Boynton FDD, Ericsson AC, et,al. Doxycycline induces dysbiosis in female C57BL/6NCrl mice. BMC Res Notes. 2017 Nov 29;10(1):644. doi: 10.1186/s13104-017-2960-7. PMID: 29187243; PMCID: PMC5708113.
| Experimentos celulares [1]: | |
Líneas celulares | Células MCF-7 y MDA-MB-468 |
Método de preparación | Las células se sembraron en placas de 96 pozos a una densidad de 5000 células/pocillo. Las células se incubaron con doxycycline a concentraciones de 0-250 µM durante 72 horas. |
Condiciones de reacción | 0-250 µM; 72h |
Áreas de aplicación | Doxycycline inhibe la viabilidad celular de las células de cáncer de mama y las mammospheres. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones C57BL/6J |
Método de preparación | Los ratones fueron asignados a una farsa, lesión cerebral Traumatic (TBI), o TBI con brazo de doxycycline. Se indujo un TBI moderado utilizando un impactor cortical controlado. La cohorte de TBI con doxycycline recibió una dosis de doxycycline (20 mg/kg) 2 horas después de la lesión y cada 12 horas hasta el día postoperative (POD) 6. |
Forma de dosificación | 20 mg/kg; p.o ; 2 veces |
Áreas de aplicación | Doxycycline tratada después de la lesión cerebral traumática de ratones mejoró la función conductual y mortora. |
References: | |
| Cas No. | 564-25-0 | SDF | |
| Formula | C22H24N2O8 | M.Wt | 444.43 |
| Solubility | DMSO : 125 mg/mL (281.26 mM; Need ultrasonic) | Storage | Store at 4°C, protect from light, stored under argon |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2501 mL | 11.2504 mL | 22.5007 mL |
| 5 mM | 450 μL | 2.2501 mL | 4.5001 mL |
| 10 mM | 225 μL | 1.125 mL | 2.2501 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)